Novel MRP1 Functionalised Sterosomes Improves The Anticancer Efficacy Of Docetaxel Against Prostate Cancer

Author : Joshua Nwabuife

Abstract :Prostate cancer is a common disease that affects men in their reproductive organ and has killed many people in different countries. Chemotherapeutic drugs delivered using the conventional delivery systems for the treatment of prostate cancer have been reported to experience some challenges including resistance. It has been suggested that if only we can try to repackage these drugs in another vehicle (delivery system) that can help transport them directly to the cancer cells, keeping them away from other healthy cells and tissues in the body, a better treatment outcome will be attained. Sterosomes are a type of vehicle (nano delivery systems) which have been shown to deliver drugs specifically to the cells they are needed, especially when functionalized with either a ligand or an antibody. Therefore, this study aimed to explore MRP1 antibody functionalized Sterosomes for the delivery of Docetaxel (one of the drugs for prostate cancer) [DTX] directly to prostate cancer cells in vitro. DTX-Sterosomes were formulated using the thin film hydration method and physiochemically characterized, for the particle sizes, polydispersity index (PDI), zeta potential charge (ζ), morphology, entrapment efficiency. The drug release study was also evaluated using dialysis bag method. In vitro anticancer efficacy of the prepared DTX-Sterosomes in comparison with the bare anticancer agents (conventional DTX) were evaluated using MTT assay. The particle sizes, PDI and ζ of the optimized DTX-Sterosomes were observed to be 150.10 ± 6.20 nm; 0.271 ± 0.01; +38.8 ± 1.41 mV, with good % Encapsulation Efficiency of DTX (~99.05%), and a sustained DTX release in 72 hours. Morphology of the DTX-Sterosomes were observed to be spherical. Growth inhibition on LnCAP using MTT assay showed the prepared DTX-Sterosomes exhibited an improved anticancer efficacy compared to the bare anticancer agents (DTX). The prepared DTX-Sterosomes is a potential candidate and could serve as a potential delivery system for DTX in the treatment of prostate cancer, subject to further anticancer study evaluations in vitro and in vivo

Keywords :Prostate cancer, drug delivery, Docetaxel, Sterosomes, MRP1 antibody, nanomedicine

Conference Name :INTERNATIONAL CONFERENCE ON RECENT ADVANCES IN MEDICAL AND HEALTH SCIENCES (ICRAMHS-25)

Conference Place Lagos, Nigeria

Conference Date 10th Oct 2025